HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15 ...

Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 ...

The key myth, Erica suggests, is the story of the origin of Rome: Romulus and Remus were abandoned in a forest and suckled by ...

The movie that offended Sigourney Weaver by existing was 2004's 'Alien vs Predator,' a movie she saw as a shameless cash-grab ...

Milla Jovovich and Dave Bautista grimly plod through this would-be fantasy epic that is hopelessly dragged down by its ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

Paul W.S. Anderson is a modern maestro of B-movie action delights, whether or not Milla Jovovich is along for the ride.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

The article introduces various animals with names and appearances reminiscent of horror fiction. These creatures, ranging from the Satanic Leaf-Tailed ...

With lax regulations and a hunting quota, the wolves are just barely getting by, the news outlet reported. Ecosystems have a fragile balance. Without a top predator, prey species can over-populate, ...